Claritev (NYSE:CTEV) Shares Break Above 200-Day Moving Average - Time to Sell?

Key Points

• Shares moved above their 200-day average of $25.47, reaching $29.06 intraday before last trading at $27.39; the article also reports a 14.1% stock gain.
• Claritev raised its 2026 revenue outlook to $1.038 billion–$1.043 billion and expects at least $1.1 billion in 2027 revenue, citing momentum related to the No Surprises Act.
• Analysts’ consensus rating is Moderate Buy, with an average price target of $44.83. The company reported $268.31 million in quarterly revenue but remains loss-making on a reported per-share measure.

Claritev (NYSE:CTEV - Get Free Report)'s share price passed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $25.47 and traded as high as $29.06. Claritev shares last traded at $27.39, with a volume of 933,110 shares trading hands.

Key Headlines Impacting Claritev

Here are the key news stories impacting Claritev this week:

• Positive Sentiment: Claritev raised its 2026 revenue outlook to $1.038 billion–$1.043 billion and forecast at least $1.1 billion in 2027 revenue, citing NSA-related momentum. The higher projections point to stronger expected demand and growth. Article: Claritev expects at least $1.1B 2027 revenue
• Positive Sentiment: Third-quarter revenue was $268.31 million, and the company’s $3.64-per-share loss was slightly narrower than analysts’ expected $3.68 loss. The loss also improved from $4.07 per share a year earlier. Article: Claritev reports Q3 loss, tops revenue estimates
• Negative Sentiment: Despite the year-over-year improvement, Claritev remained loss-making on the reported per-share measure, which may temper enthusiasm about its growth outlook. Article: Claritev reports third-quarter 2026 results

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on CTEV. Weiss Ratings reissued a "sell (d-)" rating on shares of Claritev in a research report on Monday, September 21st. Wall Street Zen raised shares of Claritev from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. Canaccord Genuity Group upped their target price on shares of Claritev from $37.00 to $43.00 and gave the company a "buy" rating in a research report on Monday, August 10th. Zacks Research raised shares of Claritev from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 13th. Finally, Citigroup reiterated a "buy" rating and set a $45.00 price target (up from $40.00) on shares of Claritev in a research report on Monday, August 10th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Claritev currently has a consensus rating of "Moderate Buy" and an average target price of $44.83.

Claritev Stock Up 14.1%

The company has a market cap of $464.26 million, a PE ratio of -1.67 and a beta of 1.05. The business has a 50-day simple moving average of $26.90 and a 200-day simple moving average of $25.47.

Claritev (NYSE:CTEV - Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported $1.77 EPS for the quarter, topping the consensus estimate of ($3.68) by $5.45. The firm had revenue of $268.31 million for the quarter. As a group, equities research analysts predict that Claritev will post -15.13 EPS for the current fiscal year.

Insider Transactions at Claritev

In other news, major shareholder Ares Management Llc bought 50,000 shares of the stock in a transaction that occurred on Friday, October 23rd. The stock was bought at an average cost of $23.53 per share, for a total transaction of $1,176,500.00. Following the acquisition, the insider directly owned 1,913,105 shares of the company's stock, valued at $45,015,360.65. The trade was a 2.68% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Tiffani Misencik sold 8,850 shares of Claritev stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $40.07, for a total value of $354,619.50. Following the completion of the transaction, the senior vice president directly owned 123,723 shares of the company's stock, valued at approximately $4,957,580.61. This represents a 6.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders bought 77,284 shares of company stock worth $1,927,655 and sold 23,687 shares worth $769,078. Corporate insiders own 7.40% of the company's stock.

Institutional Trading of Claritev

Several hedge funds have recently made changes to their positions in CTEV. Engineers Gate Manager LP acquired a new position in shares of Claritev in the second quarter valued at approximately $245,000. Integrated Wealth Concepts LLC acquired a new stake in Claritev during the 2nd quarter worth approximately $44,000. Public Investment Fund acquired a new stake in Claritev during the 2nd quarter worth approximately $43,703,438. FAS Wealth Partners Inc. lifted its holdings in Claritev by 49.5% during the 1st quarter. FAS Wealth Partners Inc. now owns 46,477 shares of the company's stock worth $759,000 after buying an additional 15,380 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in Claritev by 146.6% during the 1st quarter. Bank of America Corp DE now owns 97,795 shares of the company's stock worth $1,598,000 after buying an additional 58,133 shares in the last quarter. Institutional investors and hedge funds own 87.15% of the company's stock.

Claritev Company Profile

Claritev, formerly known as MultiPlan, provides technology-enabled services intended to help manage healthcare costs and support payment accuracy. Its offerings include access to provider networks, claims and payment solutions, and data analytics for evaluating healthcare costs and utilization. The company serves health plans, self-insured employers, third-party administrators and other participants in the U.S. healthcare system. Its services are designed to help customers identify cost-management opportunities and support more efficient healthcare transactions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.